ASCO 2015 | Updated results of a phase 1a study of anti-PDL1, MPDL3280A, in urothelial bladder cancer
Thomas Powles
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Thomas Powles, MBBS, MRCP, MD, from Barts Cancer Institute, Queen Mary University of London, London, UK, discusses the updated response and survival data of a phase 1a study of the anti-PDL1 antibody, MPDL3280A, for the treatment of patients with metastatic urothelial bladder cancer.
Related videos
4:25
Cabozantinib plus docetaxel and prednisone in mCRPC
Munjid Al Harthy
5:01
Sacituzumab govitecan in patients with previously treated mUC
Scott Tagawa
1:57
ARAMIS: efficacy and safety of darolutamide in nmCRPC
Karim Fizazi
2:14
LATITUDE: Phase III final analysis
Karim Fizazi
3:09
Analysis of OS based on early tumor shrinkage in the phase III METEOR study
Ignacio Duran
